about
CACNA1E variants affect beta cell function in patients with newly diagnosed type 2 diabetes. the Verona newly diagnosed type 2 diabetes study (VNDS) 3Association of a 62 Variants Type 2 Diabetes Genetic Risk Score With Markers of Subclinical Atherosclerosis: A Transethnic, Multicenter Study.HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study.The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE)HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia.Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women.Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes.Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.Differences in the acute effects of aerobic and resistance exercise in subjects with type 2 diabetes: results from the RAED2 Randomized TrialHaptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck StudyVariants of GCKR affect both β-cell and kidney function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study 2.Glycated haemoglobin is inversely related to serum vitamin D levels in type 2 diabetic patientsDiverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 DiabetesAssociation of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysisMetabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study).The pros and cons of diagnosing diabetes with A1CAntidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.Protection of pancreatic beta-cells: is it feasible?Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease.Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.One size does not fit all glycemic targets for type 2 diabetes.Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome.Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5.DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.Evidence of left atrial remodeling and left ventricular diastolic dysfunction in type 2 diabetes mellitus with preserved systolic function.Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.Relationships between cardiorespiratory fitness, metabolic control, and fat distribution in type 2 diabetes subjects.The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory.Endogenous hyperinsulinaemia in insulinoma patients is not associated with changes in beta-cell area and turnover in the tumor-adjacent pancreas.A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study.Antidromic sensory nerve conduction study of the digital branches of the medial plantar nerve: a novel method to detect early diabetic sensory axonal polyneuropathy.Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome.Interleukin-6 as a potential positive modulator of human beta-cell function: an exploratory analysis-the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 6.Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes-The TOSCA.IT Study.Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS).
P50
Q28481481-9432D3F0-78A6-4888-8101-39D0019A6E95Q30358502-8461C40C-D388-4448-9E62-79D728BB3899Q30700439-46F9C211-493B-4522-BB3D-283ED319AFC8Q30887060-8F650165-EAF9-4E45-BCDF-94AFC5B5559AQ33558940-57E4E2D5-6CFB-44AF-9FAD-22DBC544115CQ33889411-7B8D3CD8-D919-41ED-88FE-E26061ED123FQ34024610-6FF4E51B-90F7-4A0B-8F8A-0580B3DE5BA2Q34127486-6D071FDD-5BA4-4F1B-B3C4-65A7D5BF634FQ34495378-DEFE0EFE-AB34-44FE-ADFF-6BD879BEED33Q34506911-99281FE7-E1B5-47A9-8D3F-51F9329D09F0Q35021818-9E5B4E47-9F93-45B7-8879-E13F6B1EDBFCQ35043786-86A79906-253B-4648-A2CA-F44DF289EA4DQ35072893-EF2D18EA-6337-4B9C-BFB8-4CFC3733F919Q35620125-E2A04EB6-32BB-4516-84B7-EAE8C43B243FQ35620128-0522E552-AD5F-4541-9A16-4A669EAF61D7Q35740071-C910E6DF-DA74-4D2B-9FA1-5EB37FACFC59Q35753072-E23F313A-3661-4A26-B8CF-6CDF88DCE596Q35841126-49A05BB4-78D9-46B7-BEA4-1E579EA04497Q36783754-B1A0E28D-5CA5-4780-A40C-A3F043083852Q36861081-39E29016-BB95-48E0-BE3E-EADE8F2A59DDQ37039174-0B2D7B6E-E53B-44F8-83D8-7152FD0E887CQ37771540-DADD7D10-5B2B-4050-BDBF-41C9535EF0F4Q37906992-932EA09F-3FF6-4D3B-96A3-4300707DAEB5Q38008136-E4EBF43F-CBEA-440C-9462-5C4556235C24Q38213052-5C6B0942-83F8-4CB0-8660-1605ABA4C1C1Q38226978-37FB0302-123E-4691-A3A5-CD9C0848DD5DQ38396014-2F974BF6-D026-471A-88F8-C054EED78BF0Q38796514-2A493D2A-E949-46FA-A76A-9817579AD4EFQ38806509-4131CF06-49CB-42BB-9259-C10157876759Q39197051-B8A4BD34-1E14-4375-BEC1-519E23817C48Q39331841-62A5C717-49DC-4212-8FCE-D117A4E10488Q39691013-2444191E-4109-462E-919E-96BFCDDA46DEQ39851848-03E855DF-3EA7-4E2C-9DF4-B84994C66520Q39873860-3CE0FF34-F016-4DC7-8C6E-105631488FBEQ40045285-FDFF6DF8-C8BB-4EBE-9C70-923DC03C802CQ40153675-F8BE70A3-5EAC-4886-BCD0-FC4CC1E70920Q40179784-890CF3C1-3DA8-4B3F-9568-161D4935C524Q40354541-0D131FB9-576E-4FC3-91D3-A5248B05C072Q40612062-4CB0A2FB-346D-4072-BF4C-282EAE04BF4CQ40841910-F0778D9A-638F-4A30-A5B5-AF9ECBBEA6DA
P50
description
endocrinoloog
@nl
researcher ORCID ID = 0000-0003-1074-5164
@en
name
Enzo Bonora
@ast
Enzo Bonora
@de
Enzo Bonora
@en
Enzo Bonora
@es
Enzo Bonora
@nl
type
label
Enzo Bonora
@ast
Enzo Bonora
@de
Enzo Bonora
@en
Enzo Bonora
@es
Enzo Bonora
@nl
prefLabel
Enzo Bonora
@ast
Enzo Bonora
@de
Enzo Bonora
@en
Enzo Bonora
@es
Enzo Bonora
@nl
P227
P1153
7004495052
P21
P214
9574155286633387180009
P227
1180539680
P31
P496
0000-0003-1074-5164
P569
1953-03-18T00:00:00Z
P7859
viaf-9574155286633387180009